Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

CEO speaking at Cowen 40th Annual Health Care Conference

February 25, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley

New commercial testing facility opens in Utah

January 8, 2020
Download  full announcement Utah issues CLIA Certificate of Registration to allow patient testing New laboratory enables five-fold test volume increase to support 2020 commercial goals Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney

CMS Pricing Determination becomes effective

January 3, 2020
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that that the national price for KidneyIntelX™ set by the Centers for Medicare and Medicaid Services ("CMS") became effective as of 1 January 2020.

Medicare sets US national price for KidneyIntelX™

December 3, 2019
Download  full announcement US National pricing of $950 effective as of January 1 st , 2020 Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that that the Centers for Medicare and Medicaid Services (“CMS”) has released

Medicare Sets National Price for KidneyIntelX™

December 3, 2019
NEW YORK, Dec. 3, 2019 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule

Grant of Options

November 21, 2019
Download  full announcement  Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital of the Company

Partnership with CDPHP on KidneyIntelX

October 17, 2019
Download  full announ c ement Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians’ Health Plan,

Board appointment

October 14, 2019
Download  full  announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.
Displaying 81 - 90 of 152